Tolvaptan clinical trials
Also written Samsca, OPC-41061, Jinarc and OPC-156.
How each study uses Tolvaptan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Tolvaptan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 May 2009 · SAMSCA · NDA 022275 (FDA, Drugs@FDA)
- European Union
- 2 Aug 2009 · Samsca · EMEA/H/C/000980 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
88 studies that test it; most in 2012 (13)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 9 |
| 2012 | 13 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 55 · Other 34
Otsuka Pharmaceutical Development & Commercialization, Inc. (24) · Otsuka Pharmaceutical Co., Ltd. (19) · Otsuka Beijing Research Institute (7) · Regional Hospital Holstebro (4) · Korea Otsuka Pharmaceutical Co., Ltd. (3) · University of North Carolina, Chapel Hill (3) · Mario Negri Institute for Pharmacological Research (2) · Northwestern University (1)
Often tested with
Tested in the same studies.
Octreotide (1) · Chlorothiazide (1) · Midodrine (1) · Torsemide (1) · OPC-41601 (1)
Studies
Open first, then newest update. How each study uses Tolvaptan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 89
- A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)RecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04782258Written as Tolvaptan Suspension
- Effects of Tolvaptan in Healthy AdultsCompletedPhase 4Northwestern UniversityNCT01973140Written as Tolvaptan
- Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00201994Written as Tolvaptan
- "SALT Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00072683Written as tolvaptan
- A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)WithdrawnPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04786574Written as Tolvaptan (OPC-41061)
- Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial ProtocolCompletedPhase 1Otsuka Beijing Research InstituteNCT07166783Written as Tolvaptan
- Phase I Study Multi Dose of 7.5mg Tolvaptan in Health MaleCompletedPhase 1Otsuka Beijing Research InstituteNCT07166887Written as Tolvaptan
- A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute HyponatremiaCompletedPhase 2Otsuka Beijing Research InstituteNCT00664014Written as Tolvaptan
- Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)WithdrawnPhase 3Maisel, Alan, M.D.NCT01733134Written as Tolvaptan
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume OverloadCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03255226Written as Tolvaptan
- Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)CompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02964273Written as Tolvaptan
- Tolvaptan-Octreotide LAR Combination in ADPKDCompletedPhase 2Mario Negri Institute for Pharmacological ResearchNCT03541447Written as Tolvaptan
- Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAHStatus unknownNot applicableChinese Pulmonary Vascular Disease Research GroupNCT05569655Written as Tolvaptan
- Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal DysfunctionStatus unknownNot applicableGia Dinh People HospitalNCT04331132Written as Tolvaptan 15 MG
- Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney DiseaseCompletedPhase 4Korea Otsuka Pharmaceutical Co., Ltd.NCT03949894Written as Tolvaptan
- Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying RespondersCompletedPhase 4University of North Carolina, Chapel HillNCT02476409Written as tolvaptan
- Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With AscitesTerminatedPhase 4Korea Otsuka Pharmaceutical Co., Ltd.NCT01552590Written as Tolvaptan
- Tolvaptan Extension Study in Participants With ADPKDCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT01214421Written as Tolvaptan
- A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male SubjectsCompletedPhase 1Otsuka Pharmaceutical Co., Ltd.NCT02994394Written as OPC-41061
- A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)CompletedPhase 2Otsuka Pharmaceutical Co., Ltd.NCT01684202Written as OPC-41061
See all 89 studies that test Tolvaptan →
Given beside what is tested · 2 — Tolvaptan is usual care or a partner of the new treatment
- A Study of HRS-9057 in Patients With Heart Failure and Volume OverloadCompletedPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT06506994Written as Tolvaptan
- To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)Status unknownNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT05060523Written as Tolvaptan Tablets
As the comparator · 3 — what is tested is compared with Tolvaptan
- Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart FailureCompletedNot applicableOtsuka Pharmaceutical Co., Ltd.NCT03254108Written as Tolvaptan tablet 15mg
- Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney DiseaseStatus unknownPhase 3Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariNCT03764605Written as Tolvaptan
- Tolvaptan/Ultrafiltration in the Treatment of Acute Heart FailureCompletedPhase 4The Christ HospitalNCT01863511Written as tolvaptan
Codes
What other systems call Tolvaptan · ClinicalTrials.gg INT006772
- MeSH (NLM) D000077602TolvaptanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 21G72T1950TOLVAPTANConfirmed FDA, NLM, Wikidata
- RxNorm 358257Confirmed FDA, Wikidata
- Wikidata Q426132tolvaptanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77082TolvaptanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077602 | Tolvaptan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 21G72T1950 | TOLVAPTAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 358257 | — | Confirmed FDA, Wikidata |
| Wikidata | Q426132 | tolvaptan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77082 | Tolvaptan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.